What question did this study set out to answer?

This research aims to present interim findings from the X-TOLE open-label extension focusing on the effects of azetukalner in adults with focal epilepsy.

June 13, 2026Neurology

Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults with Focal Epilepsy: ≥42-Month Interim Analysis of the Ongoing 7-year X-TOLE Open-label Extension (P11-10.001)

View Full Paper

Ask AI

Bookmark

Authors

JFJacqueline FrenchEpilepsy Foundation RPRoger PorterCalifornia University of Pennsylvania EPEmilio PeruccaMonash University

Discussion

Member takes

Implication

Open-label extension reports positive effects of azetukalner in adults with focal epilepsy.

Key Points

This research aims to present interim findings from the X-TOLE open-label extension focusing on the effects of azetukalner in adults with focal epilepsy.
Conducted an interim analysis of an ongoing 7-year open-label extension study
Included adults diagnosed with focal epilepsy
Assessed the safety and efficacy of azetukalner over a 42-month period
Interim analysis shows favorable outcomes for adults treated with azetukalner
Significant improvement in seizure control observed over the study duration
Azetukalner demonstrated a good safety profile throughout the treatment

Cite This Study

French et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0565cc https://doi.org/10.1212/wnl.0000000000212924

View Full Paper

Ask AI

Bookmark

Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults with Focal Epilepsy: ≥42-Month Interim Analysis of the Ongoing 7-year X-TOLE Open-label Extension (P11-10.001)

Discussion

Member takes

Implication

Key Points

Cite This Study

Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults with Focal Epilepsy: ≥42-Month Interim Analysis of the Ongoing 7-year X-TOLE Open-label Extension (P11-10.001)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider